Safety, Fea s i b ility a nd  Efficacy of Su lfora ph a n e
(Avmacol Extra S tre n gt h ) i n  C h ro n ic Ki dn ey Di s ea s e – P h a s e I
Prin ci p al I n ve s tigator – T hu  H. Le, MD
1. PURPO S E OF S TUDY
We hypothesize that daily intake o f  sul f o r aphane (A vmacol Ext r a S t r ength ( E S))  can dec r ea s e kidney
disea s e prog r ession r ate and dec r ease ma r ke rs  o f  oxidative s t r e ss  and in f lammation in ch r onic kidney
disea s e (CKD )  patients. We will test ou r  hypothe s i s  in a r andomized, double - blind, placebo - controlled
Phas e 1/2 clinical t r ial in a single cente r , t w o s ite s , 3 - yea r  s tudy. Thi s  p r opo s ed s tudy w a s  s ubmitted a s  an
R01 application in r esponse to F OA P A S- 20 - 160 that encou r age s  s ubmi ss ion o f  pi[INVESTIGATOR_17371] f ea s ibility
clinical trials that will lay the f oundation f o r  la r ge r  clinical t r ial s  r elated to the p r evention/t r eatment of
CKD within the mission o f  N I DDK. We have r eceived a N otice o f  Aw a r d f o r  thi s  s tudy from
NIH/NIDDK.
There are two phases to ou r  study; each w ill have a s epa r ate Con s ent F o r m. Thi s  p r opo s al i s  o n ly for
Phas e I s tudy. Once P hase I  is complete, a ne w  s tudy w ill be s ubmitted f o r  P ha s e II . P lea s e s ee s tudy
design below f o r  details:
1. P hase I : Establish pha r macokinetic s  o f  A vmacol E S  in patient s  w ith C KD  S tage s  3-4
(first 6 months o f  the study ) . S ubject s  w ho pa r ticipate in the f i rs t pha s e o f  the s tudy may be
eligib le to pa r ticipate in the second pha s e o f  the s tudy.
We s ee k  a pp roval f or th e P h ase I o f  t he stud y wh ic h  w ill e st a b li sh  th e d o s i n g f or th e s eco nd  pha s e
of th e s t ud y .
2. BACKGROUND AND RATIONALE
In the United S tates ( U. S . ) , the p r evalence o f  ch r onic kidney di s ea s e ( C KD)  in adult s  i s  ~ 14%. The
main s tay of the r apy f o r  CKD a r e angioten s in - conve r ting enzyme inhibito rs  (A CE -Is)  o r  angioten s in
receptor blocke r s ( ARBs ) , but many CK D  patient s  s till p r og r e ss  to end s tage kidney di s ea s e ( E SKD)  – the
ultimate in f ailed p r evention. The p r evalence o f  E SKD  i s  ~  700,000, and i s  p r ojected to inc r ea s e to
between 971,000 – 1,259,[ADDRESS_16495] r ess is a maj or  molecula r  unde r pi[INVESTIGATOR_334] o f  C KD  p r og r e ss ion. I n human s , a
common deletion va r iant o f  the glutathione -S- t r an sf e r a s e μ- 1 (G S TM 1 )  gene, the G S TM 1 null allele
(GST M1(0) ), r esults in dec r eased G S TM1 enzymatic activity and i s  a ss ociated w ith highe r  level s  of
oxidative s tress. G S TM1 belongs to the s upe rf amily o f  GS T s  that a r e pha s e II  antioxidant enzyme s  and
are regulate d  by [CONTACT_17382] r  f acto r  e r yth r oid 2 -r elated f acto r  2 (Nrf 2 ) . O u r  labo r ato r y made the di s covery that
the highly p r evalent GS TM 1 ( 0 )  is associated w ith mo r e r apid C KD  p r og r e ss ion in the Afr ican A merican
Study of Kidney Disease ( AA S K )  t r ial pa r ticipant s  2 . Thi s  a ss ociation ha s  been r eplicated in the
Athero s clerosis Risk in Communities (A R I C )  s tudy 3 . I n expe r imental mou s e model s  o f  C K D or
hyperten s ion, we f ound Gstm1 knockout (KO)  mice have inc r ea s ed r enal oxidative s t r e ss , in f lammation,
and kidney inju r y, compa r ed to wild - type ( WT )  litte r mate cont r ol s  4 .
Cruciferous vegetables in gene r al, and b r occoli in pa r ticula r , a r e r ich in gluco r aphanin, a p r ecur s or of
sulforaphane (SF N )  that has been shown to have p r otective e ff ect s  again s t oxidative damage through
activation of N rf 2. We f ound that dieta r y s upplementation o f  s ul f o r aphane -r ich b r occoli powder
ameliorated kidney disease only in Gst m 1 KO  mice. S imila r ly, in the A R I C s tudy o f  nea r ly 11,000
patient s , high intake o f  c r uci f e r ous vegetable s  w a s  a ss ociated w ith lo w e r  r i s k s  o f  kidney f ailu r e, with
stronger effects in those homozygous for  the null allele (G S TM 1 ( 0/0 )) . O u r  r ecently publi s hed paper
reporting these f indings 4 was selected f o r  ne ws  r elea s e ba s ed on “it s  ove r all excellence in f u r the r ing the
field of neph r ology”, and was highlighted in s eve r al ne ws  outlet s , including S cience D aily and Reuter s
Page 1 of 13
Vers ion 3: 17NOV2022
Board: 18 J AN2022
Health.
SFN i s  cu rr ently in clinical t r ials f o r  cance r  o f  the b r ea s t, lung, and p r o s tate, a s  w ell a s  auti s m and
schizophrenia, and ca r diotoxicity fr om chemothe r apy ( Clinicalt r ial s .gov ) . H o w eve r , ve r y f e w  s tudie s
have a ss e ss ed the e ff ect o f  SF N in kidne y  di s ea s e in p r e - clinical expe r imental model s ; and, to the be s t of
our knowledge, no clinical study has been pe rf o r med to a ss e ss  the e ff ect o f  SFN  in C K D. Our
overarching objective is to test the sa f et y , f ea s ibility and e ff icacy o f  SFN  in delaying C KD  p r og r e ss ion,
and, if s o, whethe r  its e ff ect is dependent o n G S TM 1 genotype.
Once P hase I  is completed and an app r op r iate do s e i s  e s tabli s hed, w e w ill move to ou r  P ha s e I I pi[INVESTIGATOR_17372] r andomized to the s tudy d r ug A vmacol E S  and placebo f o r  6 month s . We
hope that at the conclusion o f  the 3 - yea r  s tudy, SFN  w ill be demon s t r ated to be s a f e and w ell tolerated,
with mea s urable pha r macodynamic actio ns . The r e s ult s  w ould p r ovide a s ound r ationale f o r  P ha s e III and
a future large multicente r  clinical t r ial to randomize C KD  patient s  to s tanda r d ca r e ± SFN  to dete r mine it s
efficacy in s lowing the r ate o f  decline o f  e GF R in patient s  w ith C KD  S tage s  [ADDRESS_16496] s  o f  r egulation o f  the Nrf 2 -GS T M 1 path w ay on kidney f unction.
3. ADM IN I S TRATIVE ORGANIZAT I O N
This i s  a multi - site collabo r ative study f unded by [CONTACT_941] N ational I n s titute s  o f  H ealth (NIH) . The N ephrology
Divis ion at S t r ong Memo r ial Hospi[INVESTIGATOR_307] (SMH)  w ill conduct the s tudy to en r oll patient s . S ubject s  w ill be
recruited from the Kidney Clinic in AC - 3, located at SMH , and fr om H ighland H o s pi[INVESTIGATOR_307]. U nive rs ity of
Virginia will se r ve as a data analysis site (s ee S ection #17 ) . U R M C w ill s ecu r ely t r an sf e r  de - identified
data to UVA f o r  analysis.
4. S TUDY DE S IGN
Phas e [ADDRESS_16497] a b li sh  ph ar m aco k i n e t ic s  o f  A v m acol E S  i n  p a t ie nt s with
CKD S tages 3 - 4 a nd  i n cl ud es th e f ollowi n g e nd-p oi nts:
Aim:  To d e t er m i n e th e ph ar m aco k i n e t ic s  o f  A v m acol E S  i n  p a t ie nts  w i th  C K D  St age s  3-4
and t h e i n fl u e n ce o f  G S TM1 ge n o t y p e o n  b ioavaila b ili t y. N ut r amax ha s  exp r e ss ed w illingne ss  to
provide Avmacol E S , a comme r cially available gluco r aphanin packaged w ith the active enzyme
myro s ina s e t o  conve r t gluco r aphanin to S F N . Regula r  S t r ength A vmacol ha s  been te s ted in 16 clinical
trials , https://clinicaltrials.gov/ct2/results?cond=&term=Avmacol&cntry=&state=&city=&dist =, [ADDRESS_16498] establi s h an optimal do s e f o r  C KD  S tage s  3 and 4 patient s  to achieve
similar pharmacokinetic (P K )  p r o f ile obse r ved in non - C KD  patient s . We w ill al s o te s t ou r  hypothesi s
that there i s  highe r  bioavailability o f  SF N in C KD  3 - 4 patient s  ca rr ying the G S TM 1 ( 0/0 )  genotype
compared to those ca rr ying the active GST M 1 allele.
4.1 S TUDY INTERVENTION S
STUDY DRUG: Avmacol Extra S tre n gt h  ca psu le s
IND # 158 6 89
IND HOLDER: T hu  H. Le, MD
For P ha s e I, w e will only use Avmacol ES, no placebo, to dete r mine the PK  o f  A vmacol E S  in C KD  to
guide the dose used f o r  P hase II .
Nutramax Labo r ato r ies, Consuma r  Ca r e ,  I nc., will  p r ov i d e  A v mac o l  ES  ca p s u les  free  o f  c h arge  in
bottles  shi pp e d  d i r ectl y  t o  Un i v e r sit y  o f  R o c h ester  M e d ical  Ce n ter  (UR M C)  Cli n ical  Resea r ch
Page 2 of 13
Vers ion 3: 17NOV2022
Board: 18 J AN2022
Once  a  D a y
GSTM 1  Ge notyp e C au c asians      A fr i c an  A mer i c ans
GSTM 1 (1 / 1 or  1 / 0) 50 % 73 %
GSTM 1 (0 / 0) 50 % 27 %Pharmacy  I nv esti g ati on al  Drug  S e rv ice s  (IDS).  T h e  IDS  will  st o re,  m on it o r,  a nd  d is p e n se  t h e  d r ug
directly  to  s ub jects .  D ata  fro m  t h e  st udy  will  b e  s h are d  wit h  N u trama x .
It should be noted that, compa r ed to control, SFN  at “lo w  do s e” o r  0.5 µM  concent r ation, ex vivo , i s  able
to induce exp r ession o f  the genes in human pe r iphe r al blood mononuclea r  cell s  (P B M C s)  that encode the
enzyme s  A K R1C1 and NQO1 that play a r ole in r educing r adical s pecie s  [ADDRESS_16499] be dete r mine d  f o r  the PK  analy s i s  to a ss e ss  w hethe r  the genotype in f luence s
drug metabolism. S t r ati f ied by [CONTACT_17383] 1 g r oup, patient s  w ill
be ass igned r andomly to 2 o r  4 Avmacol Ext r a S t r ength T ab l e  1 : N u m be r o f Avm a c o l Extr a  Str eng t h  T ab l e ts
tablet s  once a day, taken o r ally with f ood, a s  depi[INVESTIGATOR_17373] 1  G e not y p e 2  T a bl e t s 4  T a bl e t s
Table 1. T h e  group s  a r e  cate gor ize d  i n t o  G S TM 1  nu ll GSTM 1  ( 1 / 1  o r  1 / 0 )                 6                          6
(GSTM 1  (0/ 0)  or  GST M 1  non-nu ll  (GS TM 1  ( 1 / 1 )  o r GSTM 1  ( 0 / 0 )                            6                          6
(1/0) )  genot yp e  b ase d  on  t h e  do mi n a n t  m od el  we  ob ser v e d  i n  AASK  a nd  ARIC  c oho rts  2,3 .
Between  8 00-900  p atie n ts  a r e  see n  m on t h l y  i n  t h e  T abl e  2 Prev al e n ce
URMC  Kid n e y  Cli n ic  i n  A C -3  a nd  H ig h la nd  H o s p ital.
Among  these  p atie n ts ,  ~  60 %  h a v e  C K D  Sta g e  3  o r  4 ,
and ~  40%  of  t h e  t o tal  p atie n ts  a r e  Af rica n  America n .
The null  ge no t yp e  is  qu ite  c o mm on  i n  hu ma n  popu lati on s,  wit h  50 %  Ca u casia n s  a nd  27 %  A fr ican
Americans  b ei ng  ho m o z ygou s  for  t h e  GS TM 1  ( 0 / 0 )  allele  (see  T a ble  2  f o r  p re v ale n ce  o f  G STM1
genotypes)  [ADDRESS_16500] dose that achieve s  s imila r  t 1/2 concent r ation and AU C 0 - 8 o f  SFN  level s
as ob s erved in non - CKD patients ( 1 - 2 µM)  5,6 f o r  ou r  s a f ety and e ff icacy s tudy in P ha s e II .
Toxicitie s  a nd  g u i d eli n e s  for a d j us tme n t s , wit hd rawal s , etc.
In ca s e of any signi f icant side e ff ects, adve rs e event s  o r  unu s ual change s , do s age w ill f i rs t be halved, and
if patient’ s  s igns/symptoms do not imp r ove a f te r  3 day s , t r eatment w ill be s topped. If  s ign s / s ymptom s  are
resolved, the t r eatment will be r esumed at the lo w e r  do s e f o r  [ADDRESS_16501] ( who will be made a w a r e o f  the patient ’s  pa r ticipation )  du r ing w o r k hou rs . Af ter
work hour s , including nights and weekend s , they w ill contact [INVESTIGATOR_124] . Le w ho i s  available [ADDRESS_16502] . Le, s o that 24/[ADDRESS_16503] POPULATION
Page 3 of 13
Vers ion 3: 17NOV2022
Board: [ADDRESS_16504] era b le Subj ec t s :  We do not plan to include vulne r able s ubject s  s uch a s  child r en, p r egnant women,
fetus e s , or p r isone r s. Employees ( physician s / f ello ws)  w ill be a ss u r ed that taking pa r t in r e s ea r ch is not a
part of their duties, and r e f using to pa r ticipate in the s tudy w ill not a ff ect thei r  job. To en s u r e their
autonomy, the r esea r ch coo r dinato r  (r athe r  than the PI)  w ill con s ent them.
5. I NCLU S ION AND EXCLU S ION CRI TE RIA
Inclus ion Cri t eria :
•Age ≥ 18 yea r s and ≤ 80 yea r s
•E s timated glome r ula r  f ilt r ation r ate ( e GF R )  ≥ 25 and < 45 mL/min/1.73m 2
•Able to p r ovide consent
•Able to swallow Avmacol E S  cap s ule s
Excl us i on  Cri t eria :
•S igni f icant co - mo r bid conditions w ith li f e expectancy o f  < 1 yea r
•Unc o nt r olled hype r tension; an ave r age r eco r ded blood p r e ss u r e ≥140/90 mm H g in the pa s t 6
months
•S er u m potassium o f  > 5.5 mEq/L at s c r eening
•New Yo r k Hea r t Association Cla ss  3 o r  4 hea r t f ailu r e s ymptom s , kno w n E F  ≤ 30 %  o r  ho s pi[INVESTIGATOR_17374] f o r  hea r t f ailu r e within the pa s t 3 month s
•F acto r s judged to limit adhe r ence to inte r vention s  ba s ed on appointment attendance and
medication t r eatment compliance; PI  w ill make thi s  dete r mination
•Cur r ent pa r ticipation in anothe r  study
•Known to be p r egnant o r  planning to become p r egnant o r  cu rr ently b r ea s t f eeding; dete r mined by
[CONTACT_6270]-repo r t and medical r eco r d histo r y. A  u r ine p r egnancy te s t w ill be completed f o r  individual s
of childbea r ing potential be f o r e admini s te r ing the s tudy d r ug.
•Hi s to r y o f  dementia documented in the medical r eco r d
•On anticoagulants o r  immunosupp r e ss ion
•Unde r  t r eatment f o r  cance r
Non-Engli s h - speaking individuals will be not be included in P ha s e I  o f  the s tudy, but w ill be included in
Phas e II. If a patient cannot r ead, the con s ent f o r m w ill be r ead to them by [CONTACT_941] r e s ea r ch coo r dinato r .
6. RECRUITMENT METHOD S
Once eligible patients a r e identi f ied, ou r  re s ea r ch coo r dinato r  w ill r each out to each p r ovide r  to a s k them
if we may s peak with thei r  patients f o r  the s tudy.
Phon e/Vi d eo Call : The r esea r ch coo r dinato r  w ill contact [CONTACT_17384] s  by [CONTACT_17385] r oduce the s tudy
and gauge inte r est.
If t h e patient is inte r ested in p a r ticipating, a f ollo w- up phone o r  Zoom video call w ill be
scheduled with the patient 7 to 1 0  day s  a f te r  the initial call and r ec r uitment email i s  s ent.
Page 4 of 13
Vers ion 3: 17NOV2022
Board: 18 J AN2022
Email: One rec r uitment email will be sent to eligible patient s  a f te r  the s tudy i s  int r oduced by [CONTACT_17386] r bally ag r eed to r eceive r ec r uitment email communication s . The s tudy team member
will obtain thei r  pe r mission to use email, p e r  the f ollo w ing: “Becau s e U R M C can ’ t cont r ol the s ecu r ity of
email me ss ages once we send them, we need you r  pe rm i ss ion to e m ail you. D o you want to r eceive the
link to the consent via email? ” . P e r mission w ill be obtained be f o r e a PDF  o f  the I RB app r oved con s ent
form and s tudy f lye r  is sent via email f o r  thei r  r evie w .
The email will include a copy o f  the in f o r med con s ent; a s tudy f lye r ; an ag r eed time f o r  a fo llow-
up call, to occu r  eithe r  by [CONTACT_648] o r  Zoom video, f o r  the r e s ea r ch coo r dinato r  to r evie w  the con s ent form
and di s cu ss  the patient ’ s pa r ticipation f u r the r .
While the subject is on the phone, ou r  r e s ea r ch coo r dinato r  w ill p r ovide the option o f  r evie w ing
the con s ent f o r m eithe r  by [CONTACT_648] o r  via zoom. H o w eve r , obtained/documented con s ent w ill occu r  in
person a s  noted in S ection 7.
Mail: M ailing the in f o r med consent f o r m w ith a cove r  lette r  that w ill in s t r uct the potential s ubject not to
sign/date the consent f o r m as f ollow up p h one o r  Zoom call w ill be made by [CONTACT_941] s tudy coo r dinato r  to
review with them. The consent will not be s igned/ r etu r ned via US  po s tal; all con s ent w ill be obtained in
person; refer to S ection 7. Consent Pr oce ss .
Flyer : S tudy f lye r s will be posted in Kidney Clinic in A C - [ADDRESS_16505] voice mail w ill r eceive f ollow up
phone call b y  the study coo r dinato r , pe r  the f ollo w  up r ec r uitment phone s c r ipt s ubmitted f o r  I RB r eview.
7. CON S ENT PROCE SS
o I n f o r med consent will be obtained by [CONTACT_941] r e s ea r ch coo r dinato r  and documented via a signed
consent f o r m, and sto r ed in a cabinet in a locked r oom.
o The consent will be obtained in - pe rs on w hen the patient p r e s ent s  to the K idney Cli n ic for
their r outine f ollow up.
o To minimize coe r cion, the re s ea r ch coo r dinato r , and not the patient ’s  neph r ologi s t, will
explain to the patient the pu r po s e o f  the s tudy and go ove r  the con s ent f o r m, and give them
the oppo r tunity to ask question s . The patient w ill al s o be given the oppo r tunity to take the
consent f o r m home with them and take a s  much time needed to look ove r  the con s ent f orm.
o If  mo r e time is r equested by [CONTACT_102], f u r the r  f ollo w- up s  w ill occu r  ove r  the ph o ne to
answe r  questions, conce r ns, and di s cu ss  pa r ticipation.
o The r esea r ch coo r dinato r  w ill a s k the patient to s umma r ize the s tudy to en s u r e their
unde r standing.
o The I nvestigato r  o r  r esea r ch coo r dinato r  w ill give a copy o f  the s igned con s ent f o r m to the
subject and sto r e the o r iginal app r op r iately in a cabinet in a locked r oom.
o A check - box f o r  consent to contact s ubject s  f o r  f utu r e r e s ea r ch w ill be an option w ith con s ent for
this study.
Certific a te o f  Co nf ide n tiality :
The study is f unded by [CONTACT_941] N ational I n s titute o f  H ealth, and the r e f o r e the Ce r ti f icate of
Conf identiality ( CoC )  is automatically included a s  pa r t o f  the notice o f  a w a r d. La n guage
regar ding the Ce r ti f icate o f  Con f identiality w ill be included in the con s ent f o r m.
8. S TUDY PROCEDURE S
Page 5 of 13
Vers ion 3: 17NOV2022
Board: 18 J AN2022
SCREEN I NG PROCEDURE S:
Avmacol E S  has not been tested in patient s  w ith C KD . S ince s ul f o r aphane (SFN)  and it s  metabolite s  are
cleared by [CONTACT_10521], to establish a sa f e do s e f o r  ou r  s tudy pa r ticipant s , f o r  P ha s e I  o f  the s tudy, w e will
first perform P K analysis in CKD S tage 3B to 4 patient s  w ith e GF R bet w een 25 – 45 mL/min/1.73m 2
who meet the inclusion c r ite r ia below. The e GF R r e s ult s hould be w ithin a 2 w eek w indo w  at the time of
screening. If eG F R testing was pe rf o r med longe r  than 2 w eek s , the r e s ea r ch coo r dinato r  w ill r each out to
the patient ’ s  p r ovide r  to ask f o r  r epeat testing.
Our re s earch coo r dinato r  will use eReco rd  E M R to s c r een patient s  f o r  en r ollment ba s ed on inclu s ion and
exclu s ion crite r ia listed above in #5. Each w eek, the r e s ea r ch coo r dinato r  ( RC )  w ill s c r een s ubject s
scheduled to visit to the Kidney Clinic in the upcoming [ADDRESS_16506] consent is obtained:
A total of 2 in - pe r son study visits will occu r  f o r  the P ha s e I  s tudy. The f i rs t vi s it (A C3 o r  H ighland
Hospi[INVESTIGATOR_307]) i s  expected to last f o r  1 hou r . The s econd vi s it w ill only occu r  at the Clinical Re s ea r ch Center in
Strong M emo r ial Hospi[INVESTIGATOR_307] (S MH )  and will take place on day [ADDRESS_16507] up to 9-hou r s to allow biospecimen c o llection s  at 5 s epa r ate inte r val s .
RANDOM I ZATION :
As noted in S ection 4.1 S tudy I nte r vention s , g r oup s  w ill be s t r ati f ied by G S TM 1 g r oup, patient s  w ill be
assigned randomly to 2 o r  4 Avmacol Ext r a S t r ength tablet s  once a day, taken o r ally w ith f ood, a s
depi[INVESTIGATOR_17375] b le 1 (b elow ) . The g r oup s  a r e catego r ized into G S TM 1 null (G S TM 1 ( 0/0 )  o r  G S TM 1 non-
null ( GS T M1 ( 1/1 )  o r  ( 1/0 ))  genotype ba s ed on the dominant model w e ob s e r ved in AASK  and ARIC
cohort s . We do not anticipate di ff iculty obtaining the di ff e r ent genotype g r oup s , a s  75 %  o f  Cauca s ian s
are either GS TM 1 ( 1/1 )  o r  ( 1/0 ) , and 2 5  %  a r e G S TM 1 ( 0/0 ) . A pp r oximately 65 %  o f  patient s  in our
Kidney Clinic a r e Caucasians. I n A fr ican A me r ican s /black s , app r oximately 25 %  a r e G S TM 1 ( 1/1), 50%
are GS T M1 ( 1/0 ) , and 25 %  a r e GS TM 1 ( 0/0 ) . A pp r oximately 30 %  o f  patient s  in ou r  K idney Clinic are
African Ame r icans. Randomization will be pe rf o r med by [CONTACT_17387]  w ho w ill be p r ovided the patient s ’
eGFR and G S TM1 genotypes. S ince thi s  i s  a PK  s tudy, the inve s tigato rs  w ill not be blinded to the
randomization.
Visit 1 (1 h o u r )  a t  AC3 or Hig h la nd  Ho sp i t al Proce du re s:
Buccal S wa b:  A buccal ( cheek )  swab will be obtained fr om the s ubject to ext r act DNA  f o r  G STM1
genotypi[INVESTIGATOR_17376] n t  t o  group s  as  ou tli n e d  i n  T a ble  1 .  ( b el o w).  Ge no t yp i ng  will  b e  p erf or med  as
previousl y  don e  2 .  T h e  pro cessi ng  o f  DNA  a nd  g e no t yp i ng  will  b e  c o m p lete d  wit h i n  5  bus ine ss  days .
Drug Do s i n g :  I n - pe r son at the time o f  thei r  s tudy vi s it, patient s  in each do s e g r oup w ill be p r ovided 2 or
4 tablet s  to be taken at home once a day with f ood f o r  7 day s .
Table  1 : N u m be r o f Avm a c o l Extr a  Str eng t h  T ab l e ts
Once  a  D a y
GSTM 1  G e not y p e 2  T a bl e t s 4  T a bl e t s
GSTM 1  ( 1 / 1  o r  1 / 0 )                  6                          6
NIH PROMI S GSTM 1  ( 0 / 0 ) [ADDRESS_16508] io nn aire :F o r each
subject, clinical status and symptoms w ill be monito r ed u s ing thi s  que s tionnai r e f o r  ga s t r ointe s tinal
symptom s . P ape r  copi[INVESTIGATOR_014] o f  this su r vey w ill be admini s te r ed to the s ubject at V i s it 1 and each f orm i s
Page 6 of 13
Vers ion 3: 17NOV2022
Board: 18 J AN2022
expected to take 20 minutes to complete. The que s tionnai r e w ill be completed in - pe rs on a s  pa r t o f  V i s it 1,
at home on Day 3, and r etu r ned with the n ext in - pe rs on vi s it on D ay 7 (V i s it 2 ) .
Kansas  Ci ty  C a rdiom y op at h y  Qu es tionn a i re  (M odi f i e d ):  F or  ea c h  s ubje ct, c lini c al  st a t u s and
symp t o ms w ill be  mon it ored  u si ng  t h is que st ionnaire  f or  hear t f ailure  sy mp t om s. P aper  c op ies of
this s u rv e y will be  pro vi ded  t o  t he  s ub j e ct a t V i s i t [ADDRESS_16509] ed  t o  t a k e  abou t 30  minu tes
each t o  c o m p l e t e . The questionnai r e will be completed in - pe rs on a s  pa r t o f  V i s it 1, at home on D a y  3,
and returned with the next in - pe r son visit on D ay 7 (V i s it 2 ) .
General Q u es t io nn aire :  Each patient will al s o complete a b r ie f  que s tionnai r e o f  ho w  they f eel each day,
including any new symptoms. S ubjects are expected to complete the gene r al que s tionnai r e once each day
throughout t h e [ADDRESS_16510] Trac k i n g C h ar t : F o r  each subject, a cha r t w ill be p r ovided to help t r ack daily s tudy d r ug intake
and que s tionnai r es. The f o r m will also include the s ubject ’s  s tudy d r ug do s age and 7 - day s tudy timeline.
Visit 2/Day 7 Proce du res ( 8 - Ho u rs )  a t  C li n ical R e s earc h  C e nt er i n  St ro n g Me m orial Ho sp i t al :
On day 7, s ubjects will come to the Clinical Re s ea r ch Cente r  at SMH , take thei r  do s e w ith f ood. Thi s  vi s it
will la s t for about [ADDRESS_16511] u g package s o the s tudy team can account for the numbe r  o f
tablet s  taken during the 7-day period.
Bloo d  S amples :  Blood collection will involve one venipunctu r e 4 mL blood s ample obtained at 0, 1 hour,
2, 4, and 8 hou r s. The samples may be obtained by a phlebotomi s t in the Clinical Re s ea r ch Center or
Strong M emo r ial Hospi[INVESTIGATOR_17377]. A n IV- line w ill be placed f o r  the blood d r a ws  to minimize
needle s ticks. A total numbe r  o f  two collection attempt s  w ill be allo w ed f o r  each time inte r val.
Urin e S amples : U r ine collection will involve one s ample o f  a minimum o f  [ADDRESS_16512] r omet r y S ha r ed Re s ou r ce s  Labo r ato r y (MS RL )  Co r e at the U nive rs ity of
[COMPANY_002] s ter Medical Cente r .
Med ical Recor d  EMR :  No r esea r ch data (G S TM 1 genotype o r  blood SFN  level )  w ill be included in the
subject’ s  medical r eco r d. Labo r ato r y data that a r e pa r t o f  the patient s’  clinical ca r e w ill be conve y ed to
the patient s  as standa r d o f  ca r e. F o r  the study, w e w ill collect demog r aphic in f o r mation, including age,
sex, height, weight, r ace, past medical hi s to r y – s peci f ically hi s to r y o f  hype r ten s ion, hea r t f ailure, and
etiology of kidney disease, i f  any -  and b lood p r e ss u r e data. Re s ea r ch data w ill not be conveyed to the
patient s . While not anticipated, incidental f inding s  that might have health con s equence s  f o r  the individual
subject will be add r essed as clinically indicated.
As thi s  i s  co n ducted unde r  an I ND, the sample s  w ill be s to r ed f o r  2 yea rs  a f te r  ma r keting app r oval or for
5 year s , whicheve r  is late r . S hould additional te s t s  be deemed in f o r mative o r  mechani s tic to enhance
Page 7 of 13
Vers ion 3: 17NOV2022
Board: [ADDRESS_16513] r oyed a f te r  5 yea r s.
Genetic  Re s e a rc h  Pr o ce du res:  A s  me n ti on e d  a bov e,  t h e  G S TM 1  nu ll  g e no t yp e  is  qu ite  c o mmon  in
human  pop u lati on s ,  w it h  50 %  Ca u casia n s  a nd  27 %  Africa n  America n s  b ei ng  ho m o z ygou s  fo r  the
GSTM1  (0/0 )  allele .  W ho le  g e no mic  se qu e n ci ng  will  no t  o cc u r.  N o  g e n etic  c oun seli ng  will  be
provided  t o  t h e  s ub ject .  We  w ill  g e no t yp e  G S TM 1  t o  assess  w h et h er  it  i n fl u e n ces  PK/d r ug
metabolism  of  SFN  fro m  Av mac o l .
Com p letio n  o f  th e f irs t  ph ase: To ensu r e patient s a f ety a f te r  they have completed o r  s topped the s tudy
drug, our re s ea r ch coo r dinato r  will call subject s  a f te r  about [ADDRESS_16514] S
Sulfora ph ane/Av m acol E S  (Stud y Dr u g )
There are s ome potential r isks to pa r ticipant s  s ince w e a r e int r oducing a w ell - tole r ated s tudy d r ug in other
clinical trials but has not been p r eviousl y  te s ted in C KD  patient s . We take ca r e f ul p r ecaution s  b y fir s t
establi s hing an optimal dose o f  Avmacol E S  in C KD  patient s  u s ing r epo r ted peak pla s ma concent r ation s
in trial s  that we r e conducted in patients without kidney di s ea s e. Ba s ed on the multiple clinical t r ial s  that
have been done with Avmacol o r  the actual s ul f o r aphane compound in othe r  di s ea s e s , w e do not
anticipate any se r ious r isks. The most common s ide e ff ect s  a r e ga s t r ointe s tinal, including nau s ea and
dyspep s ia, which a r e amelio r ated when taken w ith f ood.
Although not r epo r ted in any ea r lie r  t r ial, the r e i s  the po ss ibility o f  an alle r gic r eaction to the
study drug. This r eaction may be mild, such a s  a s kin r a s h, o r  mo r e s eve r e s ymptom s  like sw elling of the
throat, low blood p r essu r e, and sho r tness o f  b r eath. I n r a r e ca s e s , a s eve r e r eaction could cau s e deat h .
Risks  of Bloo d  Draw
The mo s t common r isk is pain, bleedin g , o r  b r ui s ing at the s ite o f  the blood d r a w . O the r  r i s k s  i n clude
redne ss , and swelling o f  the vein and in f ection, and a r a r e r i s k o f  f ainting.
Risks  of B u ccal S wa b
The ri s k i s  minimal. The r e is r isk o f  not obtaining adequate s ample f o r  DNA  ext r action.
Risks  of Uri n e S a mp le
The ri s k i s  minimal. The r e is r isk o f  spi[INVESTIGATOR_17378] u r ine onto clothe s .
Risks  of Preg n a n cy: The e ff ect o f  sul f o r aphane on the f etu s  i s  not kno w n. The patient w ill be advi s ed to
immediately stop taking the d r ug i f  p r egnancy i s  s u s pected and noti f y the r e s ea r ch team.
Risk  of Di s clos u re o f  Privacy a nd  Co nf i d e nt iali t y
Other potential r isks involve violations o f  con f identiality. Pr ocedu r e s  f o r  a ss u r ing con f identiality are
discu ss ed below.
Risks  to S ocial/E m o t io n al Well - Bei n g
We do not anticipate any psychological, social o r  legal r i s k s  beyond tho s e r elated to pa r ticipation in a
clinical s tud y .
Page 8 of 13
Vers ion 3: 17NOV2022
Board: [ADDRESS_16515] f o r  pa r ticipation o f  the study. A vmacol E S  w ill be p r ovided by N ut r amax w ithout co s t to
the patient s .
12. PAYMENT FOR PARTICIPATIO N
Each of the study pa r ticipants will r eceive $100.00 in a p r epaid V i s a ca r d, divided into t w o payment s  of
$50.[ADDRESS_16516] s  w ill al s o r eceive the full
compen s ation o f  $100.
13. S UBJE C T WITHDRAWAL S
1. P articipants ’  decision to withd r a w  fr om the s tudy f o r  any r ea s on
2. Development o f  side e ff ects that a r e not r e s olved by [CONTACT_17388] s e r eduction
3. F ailu r e to adhe r e to the study p r otocol
4. Rel o cation r esulting in inability to f ollo w  up pe r  p r otocol
5. Become p r egnant
6. Ne w  diagnosis o f  hea r t f ailu r e, ca r diova s cula r  event, li f e th r eatening in f ection, o r  cance r
In the event that a patient d r ops out the study due to r ea s on s  li s ted above, w e w ill r ec r uit an additional
patient to replace.
Once treatment is stopped f o r  any r eason ,  patient s  w ill continue to be f ollo w ed a s  pa r t o f  s tanda r d of care
for CKD. Long - te r m f ollow up data will continue to be collected, including thei r  blood p r e ss u r e, eGFR,
and proteinu r ia.
RETURN O F  RE S ULT S :
Once the s tudy is completed, we will send s ubject s  a s umma r y o f  the r e s ult s  and w hat they mean.
Subject s  will not r eceive thei r  own individual r e s ult s .
14. PR I VA C Y AND CONFIDENTIAL I T Y  OF SU BJE C T S  AND  R E S E ARC H DA T A
The re s earch team consists o f  URMC clinical p r ovide rs  (N eph r ologi s t s)  and a s  s uch have acce ss  t o  all of
the relevant clinic r eco r ds. S tudy data w ill be collected and managed u s ing RE D Cap elect r onic data
capture tool s  hosted at URMC. S tudy data w ill be di r ectly ente r ed into RE D Cap w hich i s  a HIPAA
Page 9 of 13
Vers ion 3: 17NOV2022
Board: [ADDRESS_16517] to patient con f identiality, the r i s k o f  imp r ope r  acce ss , u s e, o r  di s clo s u r e o f  pa r ticipant data i s
minimized th r ough the f ollowing p r ocedu r e s :
1. All study pe r sonnel and r esea r che rs  a r e r equi r ed to s ign a pledge o f  con f identiality, committing to
safeg ua r d the study data du r ing its collection, analy s i s , and a f te r  the s tudy i s  concluded.
2. P hysical ( pape r)  questionnai r e f o r m s  and media containing the elect r onic data f ile s  w ill be kept in
locked f iles with r est r icted access.
3. Data Key -  Each subject will be a ss igned a s tudy ID  numbe r  w hich w ill be u s ed to label their
data/samples and linked to the subject on a s epa r ate key. O nly [CONTACT_17391] and the inve s tigative team
will have access to the data key a n d it w ill be s to r ed s epa r ately fr om the data s et.
4. The data upon which statistical analy s i s  w ill be conducted w ill contain pa r ticipant number s  a s
unique identi f ie r s in lieu o f  name s , medical r eco r d numbe r , o r  s ocial s ecu r ity numbe rs . The s e
data a r e conside r ed identi f iable, but not di r ectly identi f iable.
When data gene r ated fr om this study i s  s ha r ed f o r  analy s i s , only de - identi f ied in f o r mation will be
exchanged. N o p r otected health in f o r mation w ill be s ha r ed w ith any collabo r ato r  no r  u s ed in any
publication s . Only agg r egate r esults, not individual data, w ill be publi s hed in r epo r t s  o r  manu s c r ipts.
15. DATA / S AMPLE S TORAGE FOR F U T UR E US E
Sample s  will be collected, p r ocessed, and s to r ed f o r  f utu r e u s e in an app r oved - [ADDRESS_16518] to sha r e w ith othe r  r e s ea r che rs  and/o r  utilize s ubject data and
biospecimens collected du r ing this study f o r  f utu r e r e s ea r ch pu r po s e s . Thi s  include s  s ubject s ample s ,
health information, and genotype G S TM1 data. S ubject s  w ill be p r ovided the oppo r tunity to opt - in or opt-
out of permitting the study team to utilize thei r  data and bio s pecimen s  du r ing the I C F  p r oce ss . S hould
subject s  agree to allow the study team t o  utilize data and bio s pecimen s  f o r  f utu r e r e s ea r ch, the data and
biospecimens would be used to f u r the r  unde rs tand kidney di s ea s e and othe r  r elated topic s .
The clinical data and associated biospecimen s  w ill be identi f ied only by [CONTACT_941] S ubject ID  u s ed in the current
study. Compute r s housing the data a r e secu r ed in locked r oom s  w hen not in u s e. A ll data f ile s  and d erived
analytic data f iles a r e enc r ypted f o r  sto r age and t r an s po r t. S tudy data w ill be kept on pa ssw o r d p r otected
computer s  at URMC, REDCap and UR Box p r og r am. S igned con s ent f o r m s  w ill be s to r ed in a cabinet in
a locked room.
16. DATA A ND S AFETY MONITORI N G PL AN
Med ical Sup ervisio n  a nd  Su rveilla n ce o f  Stud y Subj ec ts . The PI , Dr . Le, w ill be r e s pon s ible for
supervi s ion o f  the enti r e study. Clinical s tatu s  and s ymptom s  w ill be monito r ed u s ing comp r ehen s ive
Page 10 of 13
Vers ion 3: 17NOV2022
Board: 18 J AN2022
health s creening tools, including the N IH  P R OMIS  que s tionnai r e f o r  ga s t r ointe s tinal s ymptom s , and a
modified Kansas City Ca r diomyopathy que s tionnai r e f o r  hea r t f ailu r e s ymptom s  that w ill be r elevant to
both patients with a histo r y o f  hea r t f ailu r e (NY  H ea r t Ass ociation Cla ss  3 and 4 hea r t f ailu r e s ymptom s
are excluded )  and patients without p r e - exi s ting hi s to r y o f  hea r t f ailu r e.
Data S afety Mo n i t ori n g Boar d  ( D S MB). We have al r eady identi f ied 3 membe rs  at U R M C w ho are not
inves tigators in the study to se r ve on the DSM B:
1. Ronnie Guillet, MD, P hD, Pr o f e ss o r  o f  P ediat r ic s . O ve r  the cou rs e o f  he r  ca r ee r , Dr . G uillet ha s
been involved in two p r ima r y a r ea s  o f  r e s ea r ch, both f ocu s ed on bette r  unde rs tanding neonatal
development and inju r y: neo n atal b r ain inju r y ( neonatal s eizu r e s  and hypoxic i s chemic
encephalopathy )  and thei r  t r eatment and neonatal acute kidney inju r y ( epi[INVESTIGATOR_623], cont r ibuting
and amelio r ating f acto r s ) . These e ff o r t s  and othe rs  have r e s ulted in nea r ly [ADDRESS_16519] . Bu s hin s ky ha s
published nea r ly 120 pee r-r evie w ed a r ticle s  and ove r  60 invited r evie ws , chapte rs  and editorial s
focusing on diso r de r s o f  divalent ion metaboli s m. H e ha s  conducted la r ge clinical t r ial s , including
“The e ff ects o f  the potassium - binding polyme r  pati r ome r  on ma r ke rs  o f  mine r al metaboli s m
(CJAS N 2019 ) ”, “Veve r ime r  ve r su s  placebo in patient s  w ith metabolic acido s i s  a ss ociated with
chronic kidney disease: a multicente r , r andomized, double blind, cont r olled, pha s e 3 t r ial ( Lancet
2019 )”, and “Long - te r m sa f ety a n d e ff icacy o f  veve r ime r  in patient s  w ith metabolic acido s i s  in
chronic kidney disease: a multicente r , r andomized blinded placebo - cont r olled, 40 -w eek exten s ion
(Lance 2019 ) ”.
3. Dongmei Li, P hD, Associate Pr o f e ss o r  P ublic H ealth S cience s , in the Clinical and T r an s lational
Science I nstitute ( CT SI) . S he ha s  mo r e than ten yea rs  o f  expe r ience conducting s tati s tical
methodology r esea r ch, teaching, mento r ing public health s tudent s , and p r oviding consulting
services f o r  biomedical r esea r ch. S he i s  s e r ving a s  Pr og r am D i r ecto r  o f  the Biomedical Data
Science Ce r ti f icate Pr og r am co - spon s o r ed by [CONTACT_17389] D epa r tment o f  P ublic H ealth S cience s .
She also se r ves as the Biostatistic s  and I n f o r matic s  Co r e D i r ecto r  o f  an FDA / N C I  f unded [ADDRESS_16520] s . F o r  he r  bio s tati s tic s  metho d ology
resea r ch, she has wo r ked on both genetic and genomic data analy s i s  ( gene exp r e ss ion, SNP , DNA
methylation, Ch IP- seq, ATAC - seq, and p r oteomic s)  f o r  mo r e than ten yea rs , and ha s  developed
new statistical analysis methods and co rr e s ponding analy s i s  package s  in R/Bioconductor for
DNA methylation a rr ay and RNA -S eq data analy s i s . S he al s o developed a ne w  method and R
package to cont r ol f o r  multiple testing e rr o r  r ate s  in genomic and genetic data analy s i s .
The D SM B will meet at the beginning o f  the P ha s e I  and at the end o f  P ha s e I  w hich i s  anticipate d  to be
completed in [ADDRESS_16521] s  and adve rs e event s . The DS M B
will follow the N I H National Cente r  f o r  Re s ea r ch Re s ou r ce s  guideline s  including:
1. Review subject r ec r uitment, att r ition, and mino r ity involvement
2. Monito r  sa f ety o f  r esea r ch p a r ticipant s  by r evie w ing unblinded data f o r  s ide e ff ect s  and
adve r se events
3. Assu r ing compliance with r equi r ement s  r elating to r epo r ting o f  adve rs e event s
Page 11 of 13
Vers ion 3: 17NOV2022
Board: 18 J AN2022
4. Assu r ing data accu r acy and p r otocol compliance, and that any action that r e s ult s  in the
tempo r a r y o r  pe r manent suspen s ion o f  the p r otocol i s  r epo r ted to all app r op r iate monitoring
bodies, including the I RB, and the NIH  Off ice o f  Biotechnology A ctivitie s .
Should any se r ious adve r se event occu r , we w ill convene a meeting w ith the DSM B to dete r mine w hether
the study s hould be suspended until additional r evie w  can be p r ope r ly pe rf o r med.
17. DATA ANALY SIS  PLAN – To b e p erforme d  at UVA
Data  ha rm o niz a ti on , m anage m en t and  an alysis
1. D e v e l op  da t a  m anage m en t and  st a tistic a l ana lysis p l an .
2. W o rk wit h  t he  t ea m and  CTSI a t U R M C cl o s e ly t o  de si gn  a  un ifi ed  managemen t syst em  f or  da t a
collecti on , tr an sf e r be tw een  t he  st ud y sit e  and  managemen t.
3. D a t a  o v e rsi gh t and  m on it o ri ng  du ri ng  da t a  c o ll e cti on  and  i n t egra ti on .
4. H a rm on iz e  t he  st ud y da t a  e l e m e nts and  v ar i ab l e s f rom  cli n ic a l and  l abora t or y and  b i o c hemi c al
data
5. V a li da t e  da t a  qua lity and  pe rf o rm cl ean i ng  pro c e ss.
6. W o rk cl o s e ly wit h  t he  PI [INVESTIGATOR_17379] n ic a l i n v e sti ga t or s t o  de t erm i ne  appropr i a t e  st a tistic a l me t hod s
and m a c h i ne  l ea r n i ng  a l go rit h ms f or  t he  cli n ic a l h y po t he s e s. C u tti ng-edge  st a tistic a l me t hod s and
innov a tiv e  da t a  sci en c e  t oo ls will be  c on si dered  or  adop t ed .
7. Pr epa r e  t he  ana lytic a l da t a s e ts and  per f orm  pre- st a t ed  st a tistic a l ana lys e s.
8. Pr epa r e  t he  fi na l r e s u lts f o r m anus c r i p t w r iti ng  and  s ubm issi on , c on f eren c e  pre s en t a ti on s a n d
public a ti on s.
The data for sa f ety and f easibility assessment w ill be s umma r ized de s c r iptively w ith r e s pect to a d ver s e
event s  and compliance with Avmacol E S  intake. The g r oup -s peci f ic data w ill be s umma r ized and
reported a s  mean ± S D f o r  continuous mea s u r e s  and a s  fr equency and pe r centage f o r  catego r ical mea s ure s
and their diffe r ences will be compa r ed using t w o -s ample t - te s t s  o r  Chi -s qua r e te s t.
18. P I  over s ig ht  f or mu l t i - si t e researc h
The UR PI  [INVESTIGATOR_1317] r esponsible f o r  the f ollo w ing:
A. Communication: The UR P i w ill noti f y the S ite PI  o f  the R S RB s ite app r oval and provide
site app r oval lette r  as well a s  copie s  o f  the mo s t cu rr ent ve rs ion o f  the s tudy mate r ial s  via
email. The UR PI  [CONTACT_832] r esponsible th r oughout the cou rs e o f  the s tudy to p r ovide all m o dified
documents and I RB app r oval lette rs  to UVA  s ite PI .
B. S upe r vision o f  study activitie s  at the s ite: The U R PI  w ill conduct r egula r  meeting s  w ith the
site PI  [CONTACT_1639] r eview study activitie s . M eeting s  w ill occu r  eve r y 3 month s  o r  s oone r  a s  so on a s
any issue a r ises by [CONTACT_17390]. Du r ing the meeting, the U R PI  w ill t r ouble s hoot s tudy - related
issues, answe r  study -r elated que s tion s , and p r ovide ve r bal/ wr itten di r ection f o r  all s tudy
activities. Meetings will be documented via meeting minute s  in the r egulato r y binde r .
C. T r aining: The UR PI  [INVESTIGATOR_17380] r e that all s tudy pe rs onnel have completed r equi r ed in s titution-
speci f ic and p r otocol - speci f ic t r aining s  and that the s e t r aining s  a r e documented app r op r iately
via C I T I  ce r ti f ication. When s tudy pe rs onnel a r e added/ r emoved, the U R PI  w ill en s ure
UVA submits these changes to the local I RB f o r  in s titutional r evie w  and app r oval. If
applicable, these changes w ill be app r op r iately documented on the D elegation of
Responsibilities Log.
D. Repo r ting: The UR PI  [INVESTIGATOR_1318] s ubmit r equi r ed in f o r mation f o r  r epo r ting, p r og r e ss  r eport s ,
 r epo r table events, non - compliance, D ata and S a f ety M onito r ing r epo r t s  and p r ovide t h e s ite
Page 12 of 13
Vers ion 3: 17NOV2022
Board: 18 J AN2022
with any R S RB dete r mination s  r ega r ding the s ubmitted r epo r t s .
E. S ite F iles and Documentatio n : As  pe r  P olicy [ADDRESS_16522] r onically in
secur e BOX URMC se r ve r s and s ha r ed w ith s tudy membe rs  only.
19. REFERENCE S
1. M cCullough, K. P ., M orgen s tern, H., S aran, R., Herman, W.H. & Robin s on, B. M .
Projecting E S RD Incidence and P revalence in the United S tate s  through 2030. J Am Soc
Neph r ol 30, 127-135 (2019).
2. Chang, J ., et al. Lo ss  of G S T M 1, a NR F 2 target, i s  a ss ociated with accelerated
progre ss ion of hyperten s ive kidney di s ea s e in the African American S tudy of Kidney
Disea s e (AA S K). Am J Phy s iol Renal Phy s iol 304, F 348-355 (2013).
3. Tin, A. , et al. The Lo ss  of G S T M 1 A ss ociate s  with Kidney F ailure and Heart F ailure. J
Am Soc Neph r ol 28, 3345-3352 (2017).
4. Gigliotti, J .C., et al. G S T M [ADDRESS_16523] of Cruciferou s  Vegetable s  in M ice and
Human s . J Am Soc Neph r ol 31, 102-116 (2020).
5. Liu, H. , et al. Biomarker Exploration in Human P eripheral Blood M ononuclear Cells f o r
Monitoring S ulforaphane Treatment Re s pon s e s  in Auti s m S pectrum Di s order. Scientific
repor t s  10, 5822 (2020).
6. Ye, L. , et al. Quantitative determination of dithiocarbamate s  in human pla s ma, s erum,
erythrocyte s  and urine: pharmacokinetic s  of broccoli s prout i s othiocyanate s  in humans.
Clin Chim Acta 316, 43-53 (2002).
7. Garte, S ., et al. M etabolic gene polymorphi s m frequencie s  in control population s . Cancer
Epi[INVESTIGATOR_17381] r ke rs  P r ev 10, 1239-1248 (2001).
Page 13 of 13
Vers ion 3: 17NOV2022
Board: 18 J AN2022